Disease | Dose of resveratrol | Model | Findings | Publish year | Ref |
---|---|---|---|---|---|
Animal studies | Â | Â | Â | Â | Â |
 Schizophrenia | 200 and 400 mg/kg | In vivo | reduced mean episodes of rearing and mean climbing scores | 2017 | [119] |
 MK-801-induced schizophrenia | 40 mg/kg or 80 mg/kg | In vivo | Increased expression of SIRT1 and BDNF, decreased oxidative stress | 2020 | [134] |
 Schizophrenia | 20 mg/kg | In vivo | Decreased VCMs | 2017 | [135] |
 MIA-induced schizophrenia | 40 mg/kg | In vivo | Ameliorated hyperlocomotion and social behavior | 2020 | [136] |
Human studies | Â | Â | Â | Â | Â |
 Schizophrenia | 200 mg/day | Human | No significant changes | 2016 | [137] |
 Schizophrenia | 200 mg/day | Human | No significant changes | 2016 | [138] |